Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02751905 · ClinicalTrials.gov registry record · Phase 1
Absorption, Metabolism, and Excretion Study of BIIB074
A Phase 1 study, sponsored by Biogen.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT02751905 is a Phase 1 study that has completed, run by Biogen. The registered enrollment target is 6 participants.
The verdict
NCT02751905, a Phase 1 study, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The primary objectives of the study are: To determine the mass balance and routes of elimination of BIIB074 and its known metabolites following administration of a single oral dose of BIIB074 in healthy male participants and To describe the pharmacokinetics (PK) of BIIB074 and its known metabolites and the disposition profiles of total radioactivity in whole blood and plasma following a single oral dose. The secondary objectives of this study are: To assess the safety and tolerability of BIIB074 in healthy participants and To identify and characterize any additional metabolites of BIIB074 in plasma, urine, and feces.
Interventions
- DRUG BIIB074
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2016-04 |
| Est. Completion | 2016-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02751905
The ClinicalTrials.gov registry entry for NCT02751905 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BIIB074 is the first listed.
NCT02751905 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02751905 about?
NCT02751905 is a clinical study titled "Absorption, Metabolism, and Excretion Study of BIIB074". The primary objectives of the study are: To determine the mass balance and routes of elimination of BIIB074 and its known metabolites following administration of a single oral dose of BIIB074 in healthy male participants and To describe the pharmacokinetics (PK) of BIIB074 and its known metabolites ...
What is the current status of trial NCT02751905?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2016-04. Estimated completion is 2016-05.
What interventions are being tested in trial NCT02751905?
The interventions under investigation include: BIIB074 (DRUG).
Who is sponsoring clinical trial NCT02751905?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.